Ferring moves to acquire Gameto in $1.38b deal

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.

Fifty-odd years into the business of helping people build families, Ferring would now like to own some of the cells as well. The Swiss pharmaceutical group has signed an agreement to acquire Gameto, a US biotech that engineers ovarian support cells to coax immature eggs toward maturity outside the body, in a deal valued at up to $1.3825 billion. Note the “up to”. That figure leans on development, regulatory and commercial milestones whose individual terms (unsurprisingly) neither company has chosen to share.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2174

Gameto

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Gameto is a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health using proprietary cell engineering technology. The company creates engineered ovarian support cells derived from induced pluripotent stem cells to enable egg maturation outside the body, substantially reducing the duration and hormonal burden of traditional in vitro fertilization protocols. Gameto's platform addresses multiple conditions affecting women's reproductive health, including infertility, menopause, and ovarian disease. The company's lead program, Fertilo, is currently in Phase 3 clinical trials in the United States and has facilitated multiple healthy births in countries where it has received regulatory approval.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE